uniQure N.V. (QURE)
| Market Cap | 1.51B |
| Revenue (ttm) | 37.51M |
| Net Income (ttm) | -125.02M |
| Shares Out | 45.92M |
| EPS (ttm) | -2.81 |
| PE Ratio | n/a |
| Forward PE | 27.93 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $32.86 |
| Previous Close | $30.48 |
| Change ($) | 2.38 |
| Change (%) | 7.81% |
| Day's Open | 33.78 |
| Day's Range | 31.85 - 33.78 |
| Day's Volume | 692,835 |
| 52-Week Range | 28.58 - 71.45 |
Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.
KING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) ...
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe ...
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sever...
uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
The Food and Drug Administration said Monday that Uniqure can resume testing its hemophilia B gene therapy, and QURE stock popped. The hold followed a patient's liver cancer diagnosis.
The FDA has removed the clinical hold on uniQure NV's (NASDAQ: QURE) hemophilia B gene therapy program after determining the company had satisfactorily addressed all identified issues related to a singl...
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sever...
Publication in Science Translational Medicine shows local striatal delivery of microRNA-gene therapy results in widespread brain huntingtin protein lowering in Huntington's disease minipigs Publication ...
~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~
LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
We believe that uniQure stock (NASDAQ: QURE), a gene therapy company, is a good buying opportunity at the present time. QURE stock trades near $30 currently and it is, in fact, down 53% from its pre-Cov...
Biotech company Uniqure said Monday an investigation shows its hemophilia B gene therapy likely wasn't the culprit in a patient's cancer diagnosis. QURE stock popped on the news report.
Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.
Uniqure NV (NASDAQ: QURE) has reported results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC) diagnosed in one patient in the HOPE-B pivotal trial of etranacogene dezap...
~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial ~
uniQure (QURE) delivered earnings and revenue surprises of 98.72% and -59.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
~ No Significant Safety Concerns Observed ~
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Ro...
Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.
A clinical hold is weighing on the biotech's shares today.
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
Uniqure NV (NASDAQ: QURE) shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study. What Happened: Lexington, Massachusetts-based uniQure said t...
Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~
The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.
LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, to...
~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~
UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announced positive...
Shares of QURE stock bounded higher Thursday after Uniqure reported promising results for its hemophilia B gene therapy. The company says the drug improved clotting protein at 26 weeks.
~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, t...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...
uniQure (QURE) delivered earnings and revenue surprises of -171.18% and -98.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in ...
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, t...
Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the s...
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~ ~ Independent Data Safety Monitoring Board Rec...
About QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; ... [Read more...]
| Industry Biotechnology | IPO Date Jun 20, 2007 |
| Stock Exchange NASDAQ | Ticker Symbol QURE |
Financial Performance
In 2020, uniQure's revenue was $37.51 million, an increase of 415.23% compared to the previous year's $7.28 million. Losses were -$125.02 million, 0.66% more than in 2019.
Analyst Forecasts
According to 19 analysts, the average rating for uniQure stock is "Strong Buy." The 12-month stock price forecast is 65.81, which is an increase of 100.27% from the latest price.